Somatic mutation of TP53 takes place in a majority of HNSCC cancers (Lawrence et al., 2015; Pérez Sayáns et al., 2019) and chromosomal loss of TP53 is associated with carcinoma in situ (Califano et al., 1996). This evidence concerns the gene TP53 and in situ carcinoma.